Press/Media items

Selective manipulation of specific receptors may pave way for new MS therapies

Press/Media: ResearchAcademic

14/10/2016

Mouse experiments with compounds having opposite actions on two receptors for tumour necrosis factor (TNF) — a key factor in neurodegeneration — explains why earlier trials of TNF blockers in multiple sclerosis (MS) went wrong, and paves the way for more selective drugs targeting the system to stop MS neurodegeneration.

The study, “Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration,” published in the journal Proceeding of the National Academy of Sciences (PNAS), also has implications for a wide range of other neurodegenerative conditions.

References

Related Publications
  1. Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration

    Dong, Y., Fischer, R., Naudé, P., Maier, O., Nyakas, C., Duffey, M., van der Zee, E., Dekens, D., Douwenga, W., Herrmann, A., Guenzi, E., Kontermann, R., Pfizenmaier, K. & Eisel, U., 25-Oct-2016, In : Proceedings of the National Academy of Science of the United States of America. 113, 43, p. 12304-12309 6 p.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (1) »

ID: 36672581